AU2017342262B2 - Apilimod compositions and methods for using same in the treatment of alzheimer's disease - Google Patents

Apilimod compositions and methods for using same in the treatment of alzheimer's disease Download PDF

Info

Publication number
AU2017342262B2
AU2017342262B2 AU2017342262A AU2017342262A AU2017342262B2 AU 2017342262 B2 AU2017342262 B2 AU 2017342262B2 AU 2017342262 A AU2017342262 A AU 2017342262A AU 2017342262 A AU2017342262 A AU 2017342262A AU 2017342262 B2 AU2017342262 B2 AU 2017342262B2
Authority
AU
Australia
Prior art keywords
apilimod
disease
subject
ethoxy
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017342262A
Other languages
English (en)
Other versions
AU2017342262A1 (en
Inventor
Chris Conrad
Marylens HERNANDEZ
Henri Lichenstein
Jonathan M. Rothberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OrphAI Therapeutics Inc
Original Assignee
OrphAI Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OrphAI Therapeutics Inc filed Critical OrphAI Therapeutics Inc
Publication of AU2017342262A1 publication Critical patent/AU2017342262A1/en
Application granted granted Critical
Publication of AU2017342262B2 publication Critical patent/AU2017342262B2/en
Assigned to ORPHAI THERAPEUTICS INC. reassignment ORPHAI THERAPEUTICS INC. Amend patent request/document other than specification (104) Assignors: AI Therapeutics, Inc.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017342262A 2016-10-12 2017-10-11 Apilimod compositions and methods for using same in the treatment of alzheimer's disease Ceased AU2017342262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662407186P 2016-10-12 2016-10-12
US62/407,186 2016-10-12
PCT/US2017/056147 WO2018071548A1 (en) 2016-10-12 2017-10-11 Apilimod compositions and methods for using same in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
AU2017342262A1 AU2017342262A1 (en) 2019-04-18
AU2017342262B2 true AU2017342262B2 (en) 2023-09-28

Family

ID=60268450

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017342262A Ceased AU2017342262B2 (en) 2016-10-12 2017-10-11 Apilimod compositions and methods for using same in the treatment of alzheimer's disease

Country Status (12)

Country Link
US (1) US20190365771A1 (enExample)
EP (1) EP3525794A1 (enExample)
JP (1) JP7199349B2 (enExample)
KR (1) KR20190067824A (enExample)
CN (1) CN110167559A (enExample)
AU (1) AU2017342262B2 (enExample)
BR (1) BR112019007214A2 (enExample)
CA (1) CA3039199A1 (enExample)
IL (1) IL265911A (enExample)
MX (1) MX2019004179A (enExample)
RU (1) RU2019113752A (enExample)
WO (1) WO2018071548A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164861A1 (en) 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CN112791078B (zh) 2019-11-13 2022-12-06 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
WO2016210372A2 (en) * 2015-06-25 2016-12-29 University Of Southern California Methods to treat neurological diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
JP6705828B2 (ja) * 2014-11-07 2020-06-03 エイアイ・セラピューティクス・インコーポレーテッド 腎癌の処置に使用するためのアピリモド
PT3215157T (pt) * 2014-11-07 2019-07-12 Ai Therapeutics Inc Apilimod para utilização no tratamento de melanoma
US10729694B2 (en) * 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
WO2016126707A1 (en) * 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
WO2016210372A2 (en) * 2015-06-25 2016-12-29 University Of Southern California Methods to treat neurological diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Currin et al. (2016) "APP controls the formation of PI(3,5)P2 vesicles through its binding of the PIKfyve complex", Cell. Mol. Life Sci., vol 73:2, pp393-408 *

Also Published As

Publication number Publication date
WO2018071548A1 (en) 2018-04-19
RU2019113752A (ru) 2020-11-13
BR112019007214A2 (pt) 2019-07-02
EP3525794A1 (en) 2019-08-21
KR20190067824A (ko) 2019-06-17
US20190365771A1 (en) 2019-12-05
CN110167559A (zh) 2019-08-23
AU2017342262A1 (en) 2019-04-18
JP7199349B2 (ja) 2023-01-05
MX2019004179A (es) 2019-09-02
RU2019113752A3 (enExample) 2021-01-19
IL265911A (en) 2019-06-30
CA3039199A1 (en) 2018-04-19
JP2019530711A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
US11957688B2 (en) Combination therapy with apilimod and glutamatergic agents
US20160287605A1 (en) Combination therapy
CN107249638B (zh) 阿匹莫德用于治疗肾癌
AU2015342876B2 (en) Apilimod for use in the treatment of colorectal cancer
US20200306255A1 (en) Compositions and methods for treating niemann pick c disease
KR20180030630A (ko) 아필리모드를 이용한 암 치료 방법
AU2017342262B2 (en) Apilimod compositions and methods for using same in the treatment of alzheimer's disease
US20240024332A1 (en) Apilimod compositions and methods of use
CA3090807C (en) Combination therapy with apilimod and glutamatergic agents
WO2025030033A1 (en) Apilimod compositions and methods of use
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ORPHAI THERAPEUTICS INC.

Free format text: FORMER NAME(S): AI THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired